Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended | |
Mar. 31, 2014 | 7-May-14 | |
Document and Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Mar-14 | ' |
Entity Registrant Name | 'IsoRay, Inc. | ' |
Entity Central Index Key | '0000728387 | ' |
Trading Symbol | 'isr | ' |
Current Fiscal Year End Date | '--06-30 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 54,392,781 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
Current assets: | ' | ' |
Cash and cash equivalents | $23,702,901 | $2,899,927 |
Accounts receivable, net of allowance for doubtful accounts of $71,377 and $52,598, respectively | 805,326 | 923,780 |
Inventory | 387,020 | 405,571 |
Prepaid expenses and other current assets | 212,079 | 214,382 |
Total current assets | 25,107,326 | 4,443,660 |
Fixed assets, net of accumulated depreciation and amortization | 1,183,067 | 1,684,282 |
Restricted cash | 181,194 | 181,149 |
Inventory, non-current | 469,758 | 469,758 |
Other assets, net of accumulated amortization | 258,619 | 276,507 |
Total assets | 27,199,964 | 7,055,356 |
Current liabilities: | ' | ' |
Accounts payable and accrued liabilities | 609,761 | 432,566 |
Accrued protocol expense | 75,057 | 25,305 |
Accrued radioactive waste disposal | 130,301 | 100,000 |
Accrued payroll and related taxes | 87,660 | 127,419 |
Accrued vacation | 117,971 | 107,578 |
Total current liabilities | 1,020,750 | 792,868 |
Warrant derivative liability | 678,000 | 104,000 |
Asset retirement obligation | 847,351 | 792,242 |
Total liabilities | 2,546,101 | 1,689,110 |
Commitments and contingencies (Note 6) | ' | ' |
Shareholders' equity: | ' | ' |
Preferred stock, $.001 par value; 7,001,671 shares authorized: | 59 | 59 |
Common stock, $.001 par value; 192,998,329 & 193,000,000 shares authorized; 54,181,444 and 34,618,517 shares issued and outstanding | 54,181 | 34,618 |
Treasury stock, at cost 13,200 shares | -8,390 | -8,390 |
Additional paid-in capital | 80,980,664 | 57,431,293 |
Accumulated deficit | -56,372,651 | -52,091,334 |
Total shareholders' equity | 24,653,863 | 5,366,246 |
Total liabilities and shareholders' equity | 27,199,964 | 7,055,356 |
Series A Preferred Stock [Member] | ' | ' |
Shareholders' equity: | ' | ' |
Preferred stock, $.001 par value; 7,001,671 shares authorized: | ' | ' |
Series B Preferred Stock [Member] | ' | ' |
Shareholders' equity: | ' | ' |
Preferred stock, $.001 par value; 7,001,671 shares authorized: | 59 | 59 |
Series C Preferred Stock [Member] | ' | ' |
Shareholders' equity: | ' | ' |
Preferred stock, $.001 par value; 7,001,671 shares authorized: | ' | ' |
Series D Preferred Stock [Member] | ' | ' |
Shareholders' equity: | ' | ' |
Preferred stock, $.001 par value; 7,001,671 shares authorized: | ' | ' |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
Accounts receivable, allowance for doubtful accounts | $71,377 | $52,598 |
Preferred stock, par or stated value per share | $0.00 | $0.00 |
Preferred stock, shares authorized | 7,001,671 | ' |
Common stock, par value per share | $0.00 | $0.00 |
Common stock, shares authorized | 192,998,329 | 193,000,000 |
Common stock, shares issued | 54,181,444 | 34,618,517 |
Common stock, shares outstanding | 54,181,444 | 34,618,517 |
Treasury stock, shares | 13,200 | 13,200 |
Series A Preferred Stock [Member] | ' | ' |
Preferred stock, par or stated value per share | $0.00 | $0.00 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Series B Preferred Stock [Member] | ' | ' |
Preferred stock, par or stated value per share | $0.00 | $0.00 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 59,065 | 59,065 |
Preferred stock, shares outstanding | 59,065 | 59,065 |
Series C Preferred Stock [Member] | ' | ' |
Preferred stock, par or stated value per share | $0.00 | $0.00 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Series D Preferred Stock [Member] | ' | ' |
Preferred stock, par or stated value per share | $0.00 | $0.00 |
Preferred stock, shares authorized | 1,671 | 0 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Consolidated Statements of Operations [Abstract] | ' | ' | ' | ' |
Product sales | $1,134,319 | $1,251,478 | $3,269,642 | $3,283,167 |
Cost of product sales | 1,083,413 | 1,065,574 | 3,329,950 | 3,276,314 |
Gross profit / (loss) | 50,906 | 185,904 | -60,308 | 6,853 |
Operating expenses: | ' | ' | ' | ' |
Research and development expenses | 153,611 | 155,137 | 470,631 | 445,785 |
Sales and marketing expenses | 245,558 | 290,812 | 931,210 | 928,962 |
General and administrative expenses | 640,732 | 564,075 | 1,805,732 | 1,678,487 |
Total operating expenses | 1,039,901 | 1,010,024 | 3,207,573 | 3,053,234 |
Operating loss | -988,995 | -824,120 | -3,267,881 | -3,046,381 |
Non-operating income (expense): | ' | ' | ' | ' |
Interest income | 556 | 83 | 1,391 | 355 |
Change in fair value of warrant derivative liability | -1,095,000 | 109,000 | -1,014,000 | 183,000 |
Financing and interest expense | ' | ' | -827 | -6 |
Non-operating income / (expense), net | -1,094,444 | 109,083 | -1,013,436 | 183,349 |
Net loss | -2,083,439 | -715,037 | -4,281,317 | -2,863,032 |
Preferred stock deemed dividends (Note 9) | ' | ' | -726,378 | ' |
Preferred stock dividends | -2,658 | -2,658 | -7,974 | -7,974 |
Net loss applicable to common shareholders | ($2,086,097) | ($717,695) | ($5,015,669) | ($2,871,006) |
Basic and diluted loss per share | ($0.05) | ($0.02) | ($0.13) | ($0.08) |
Weighted average shares used in computing net loss per share: | ' | ' | ' | ' |
Basic and diluted | 42,506,077 | 34,611,517 | 38,852,980 | 34,359,567 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 9 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ' | ' |
Net loss | ($4,281,317) | ($2,863,032) |
Adjustments to reconcile net loss to net cash used by operating activities: | ' | ' |
Allowance for doubtful accounts | 18,779 | -32,174 |
Depreciation and amortization of fixed assets | 517,548 | 563,850 |
Amortization of deferred financing costs and other assets | 23,056 | 21,036 |
Change in fair value of warrant derivative liability | 1,014,000 | -183,000 |
Accretion of asset retirement obligation | 55,109 | 50,383 |
Share-based compensation | 65,217 | 85,369 |
Changes in operating assets and liabilities: | ' | ' |
Accounts receivable, gross | 99,675 | 67,195 |
Inventory | 18,551 | 87,368 |
Other receivables | 4,516 | 2,204 |
Prepaid expenses and other current assets | -2,213 | -69,427 |
Accounts payable and accrued expenses | 177,195 | -21,525 |
Accrued protocol expense | 49,752 | 27,500 |
Accrued radioactive waste disposal | 30,301 | 36,000 |
Accrued payroll and related taxes | -39,759 | -54,654 |
Accrued vacation | 10,393 | 12,961 |
Net cash used by operating activities | -2,239,197 | -2,269,946 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ' | ' |
Purchases of fixed assets | -16,333 | ' |
Additions to licenses and other assets | -5,168 | -12,926 |
Change in restricted cash | -45 | -104 |
Net cash used by investing activities | -21,546 | -13,030 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ' | ' |
Preferred dividends paid | -10,632 | -10,632 |
Proceeds from sales of preferred stock, pursuant to underwritten offering, net | 1,478,703 | ' |
Proceeds from sales of common stock, pursuant to underwritten offering, net | 1,800,589 | ' |
Proceeds from sales of common stock, pursuant to registered direct offering, net | 13,818,927 | 3,291,977 |
Proceeds from sales of common stock, pursuant to exercise of warrants, net | 5,961,001 | 1,825 |
Proceeds from sales of common stock, pursuant to exercise of options | 15,129 | 11,309 |
Net cash provided by financing activities | 23,063,717 | 3,294,479 |
Net increase in cash and cash equivalents | 20,802,974 | 1,011,503 |
Cash and cash equivalents, beginning of period | 2,899,927 | 2,672,711 |
CASH AND CASH EQUIVALENTS, END OF PERIOD | 23,702,901 | 3,684,214 |
Non-cash investing and financing activities: | ' | ' |
Reclassification of derivative warrant liability to equity upon exercise | -440,000 | ' |
Reclassification of convertible preferred stock to common stock upon conversion | ($1,478,703) | ' |
Basis_of_Presentation
Basis of Presentation | 9 Months Ended | |
Mar. 31, 2014 | ||
Basis of Presentation [Abstract] | ' | |
Basis of Presentation | ' | |
1 | Basis of Presentation | |
The accompanying consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (IsoRay or the Company). All significant intercompany accounts and transactions have been eliminated in consolidation. Certain amounts in the prior-year financial statements have been reclassified to conform to the current year presentation. | ||
In the opinion of management, the accompanying unaudited interim consolidated financial statements and notes to the interim consolidated financial statements contain all adjustments, consisting of normal recurring items, necessary to present fairly, in all material respects, the financial position of IsoRay, Inc. and its wholly-owned subsidiaries. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company's annual report filed on Form 10-K for the year ended June 30, 2013, as it may be amended from time to time. | ||
The results of operations for the periods presented may not be indicative of those which may be expected for a full year. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading. | ||
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, the reported amounts of revenues and expenses during the reporting period and the disclosures of contingent liabilities. Accordingly, ultimate results could differ materially from those estimates. |
New_Accounting_Pronouncements
New Accounting Pronouncements | 9 Months Ended | ||
Mar. 31, 2014 | |||
New Accounting Pronouncements [Abstract] | ' | ||
New Accounting Pronouncements | ' | ||
2 | New Accounting Pronouncements | ||
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") or other standards setting bodies that are adopted by us as of the specified effective dates. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position, results of operations and cash flows upon adoption. |
Loss_per_Share
Loss per Share | 9 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Loss per Share [Abstract] | ' | ||||||||
Loss per Share | ' | ||||||||
3 | Loss per Share | ||||||||
Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. Common stock equivalents, including warrants and options to purchase the Company's common stock, are excluded from the calculations when their effect is antidilutive. At March 31, 2014 and 2013, the calculation of diluted weighted average shares did not include preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company's net loss position. | |||||||||
Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2014 and 2013, were as follows: | |||||||||
March 31, | |||||||||
2014 | 2013 | ||||||||
Series B preferred stock | 59,065 | 59,065 | |||||||
Common stock warrants | 646,811 | 1,957,033 | |||||||
Common stock options | 2,324,072 | 2,312,072 | |||||||
Total potential dilutive securities | 3,029,948 | 4,328,170 |
Inventory
Inventory | 9 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory [Abstract] | ' | ||||||||
Inventory | ' | ||||||||
4 | Inventory | ||||||||
Inventory consisted of the following at March 31, 2014 and June 30, 2013: | |||||||||
March 31, | June 30, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 165,657 | $ | 167,671 | |||||
Work in process | 181,457 | 195,323 | |||||||
Finished goods | 39,906 | 42,577 | |||||||
$ | 387,020 | $ | 405,571 |
ShareBased_Compensation
Share-Based Compensation | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Share-Based Compensation [Abstract] | ' | ||||||||||||||||
Share-Based Compensation | ' | ||||||||||||||||
5 | Share-Based Compensation | ||||||||||||||||
The following table presents the share-based compensation expense recognized during the three and nine months ended March 31, 2014 and 2013: | |||||||||||||||||
Three months | Nine months | ||||||||||||||||
ended March 31, | ended March 31, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Cost of product sales | $ | 4,500 | $ | 10,164 | $ | 13,421 | $ | 30,492 | |||||||||
Research and development expenses | 3,482 | 7,607 | 10,447 | 25,042 | |||||||||||||
Sales and marketing expenses | 879 | 1,386 | 2,636 | 4,568 | |||||||||||||
General and administrative expenses | 4,572 | 8,423 | 38,713 | 25,267 | |||||||||||||
Total share-based compensation | $ | 13,433 | $ | 27,580 | $ | 65,217 | $ | 85,369 | |||||||||
As of March 31, 2014, total unrecognized compensation expense related to stock-based options was $29,192 and the related weighted-average period over which it is expected to be recognized is approximately 0.87 years. | |||||||||||||||||
The Company currently provides stock-based compensation under four equity incentive plans approved by the Board of Directors. Options granted under each of the plans have a ten year maximum term, an exercise price equal to at least the fair market value of the Company's common stock on the date of the grant, and varying vesting periods as determined by the Board. For stock options with graded vesting terms, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. | |||||||||||||||||
A summary of stock options within the Company's share-based compensation plans as of March 31, 2014 was as follows: | |||||||||||||||||
Weighted | |||||||||||||||||
Weighted | Average | ||||||||||||||||
Average | Remaining | Aggregate | |||||||||||||||
Number of | Exercise | Contractual | Intrinsic | ||||||||||||||
Options | Price | Term | Value | ||||||||||||||
Outstanding at March 31, 2014 | 2,324,072 | $ | 1.82 | 4.3 | $ | 2,050,334 | |||||||||||
Vested and expected to vest at March 31, 2014 | 2,238,840 | $ | 1.86 | 4.23 | $ | 1,923,611 | |||||||||||
Vested and exercisable at March 31, 2014 | 2,040,732 | $ | 1.93 | 3.85 | $ | 1,714,527 | |||||||||||
There were 26,333 options exercised during the nine months ended March 31, 2014 and 31,700 options exercised during the nine months ended March 31, 2013. The Company's current policy is to issue new shares to satisfy option exercises. The intrinsic value of the employee options exercised during the nine months ended March 31, 2014 was $15,130 and the nine months ended March 31, 2013 was $13,866. | |||||||||||||||||
There were 65,000 stock option awards granted and no stock option awards granted during the nine months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Of the 65,000 options, 50,000 were director stock options issued to the Chief Executive Officer and Chairman on September 5, 2013 with an exercise price of $0.58 per share which was the closing price of the Company common stock on the day of issuance. The fair value of the stock options issued on September 5, 2013 using a Black Scholes model is $25,150 utilizing the closing price on the day of grant of $0.58 per share as the grant and exercise price, a five year term, volatility of 132.31% and a discount rate of 1.85%. | |||||||||||||||||
The remaining 15,000 were employee stock options issued to three members of management on September 6, 2013 with an exercise price of $0.59 per share which was the closing price of the Company common stock on the day of issuance. The fair value of the stock options issued on September 6, 2013 using a Black Scholes model is $6,906 utilizing the closing price on the day of grant of $0.59 per share as the grant and exercise price, a five year term, volatility of 132.31% and a discount rate of 1.77%. |
Commitments_and_Contingencies
Commitments and Contingencies | 9 Months Ended | ||
Mar. 31, 2014 | |||
Commitments and Contingencies [Abstract] | ' | ||
Commitments and Contingencies | ' | ||
6 | Commitments and Contingencies | ||
Patent and Know-How Royalty License Agreement | |||
The Company is the holder of an exclusive license to use certain "know-how" developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor's patent application was ultimately abandoned, only a 1% "know-how" royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no product sales incorporating the "know-how" and therefore no royalty is due pursuant to the terms of the agreement. Management believes that ultimately no royalties should be paid under this agreement as there is no intent to use this "know-how" in the future. | |||
The licensor of the "know-how" has disputed management's contention that it is not using this "know-how". On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time. |
Fair_Value_Measurements
Fair Value Measurements | 9 Months Ended | ||||||||||
Mar. 31, 2014 | |||||||||||
Fair Value Measurements [Abstract] | ' | ||||||||||
Fair Value Measurements | ' | ||||||||||
7 | Fair Value Measurements | ||||||||||
The table below sets forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and June 30, 2013, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category. | |||||||||||
Description | Balance at | Balance at | Input | ||||||||
31-Mar-14 | 30-Jun-13 | Hierarchy Level | |||||||||
Assets: | |||||||||||
Cash and cash equivalents | $ | 23,702,901 | $ | 2,899,927 | Level 1 | ||||||
Restricted cash | 181,194 | 181,149 | Level 1 | ||||||||
Liabilities: | |||||||||||
Warrant liability | $ | 678,000 | $ | 104,000 | Level 2 |
Preferred_Dividends
Preferred Dividends | 9 Months Ended | ||
Mar. 31, 2014 | |||
Preferred Dividends [Abstract] | ' | ||
Preferred Dividends | ' | ||
8 | Preferred Dividends | ||
On December 19, 2013, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2013 in the amount of $10,632. Dividends on the Series B Preferred Stock were last paid on December 31, 2012 as declared by the Board of Directors on December 21, 2012 in the amount of $10,632. The dividends outstanding and cumulative through December 31, 2013 of $10,632 and through December 31, 2012 of $10,632 were paid as of those dates. |
Shareholders_Equity
Shareholders' Equity | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Shareholders' Equity [Abstract] | ' | ||||||||||||||||
Shareholders' Equity | ' | ||||||||||||||||
9 | Shareholders' Equity | ||||||||||||||||
Common and preferred stock transactions | |||||||||||||||||
Series D | |||||||||||||||||
On August 29, 2013, the Company entered into an agreement to sell 3,800,985 common units, each consisting of 1 share of common stock and a warrant to purchase 0.816 shares of common stock (the "Common Units"), and 1,670 preferred units, each consisting of 1 share of Series D Convertible Preferred Stock and a warrant to purchase 1,525.23 shares of common stock (the "Preferred Units") on a firm commitment underwritten basis. The Common Units were sold at an initial per unit purchase price of $0.535 and the Preferred Units were sold at an initial per unit purchase price of $1,000. The warrants were all exercisable at $0.72 per share and had a twenty-four month term. Each share of the Series D Convertible Preferred Stock was convertible into 1,869.15 shares of common stock at any time at the option of the holder, subject to adjustment and certain ownership percentage restrictions. The preferred shares which were convertible into shares of common stock contained a beneficial conversion feature of $726,378 which was recognized as a deemed dividend to the Series D preferred shareholders on the date of issuance. This public offering resulted in gross proceeds of $3.7 million. The offering yielded approximately $3,279,292 in cash after expenses. | |||||||||||||||||
Gross proceeds from public offering | $ | 3,703,527 | |||||||||||||||
Underwriting discount | (185,176 | ) | |||||||||||||||
Legal and accounting expense | (184,514 | ) | |||||||||||||||
Listing expense | (48,500 | ) | |||||||||||||||
Other expense | (6,045 | ) | |||||||||||||||
Net proceeds | 3,279,292 | ||||||||||||||||
During January 2014, the holder of the 1,670 shares of Series D convertible preferred stock fully exercised its right to convert the 1,670 shares of Series D convertible preferred stock into 3,121,480 shares of common stock which at the time of conversion resulted in an increase in shares of common stock outstanding from 38,419,502 to 41,540,982. Subsequent to the conversion, no shares of Series D convertible preferred stock remain outstanding. | |||||||||||||||||
Common Stock | |||||||||||||||||
On March 21, 2014, the Company entered into a Securities Purchase Agreement with certain investors providing for the sale of a total of 5,644,300 shares of common stock for an aggregate purchase price of $14,675,180 at a price per share of $2.60 (the "Registered Direct Offering"). The Company received net proceeds from the offering of approximately $13,818,927 from the Registered Direct Offering which will be used to meet the Company's working capital needs and general corporate purposes. | |||||||||||||||||
Gross proceeds from registered direct offering | $ | 14,675,180 | |||||||||||||||
Placement agent fees | (733,759 | ) | |||||||||||||||
Legal and accounting expense | (72,494 | ) | |||||||||||||||
Listing expense | (45,000 | ) | |||||||||||||||
Other expense | (5,000 | ) | |||||||||||||||
Net proceeds | 13,818,927 | ||||||||||||||||
Warrant exercises | |||||||||||||||||
During the month of March 2014, the holder of the Series D warrants issued in November 2010 exercised its right to purchase 1,050,000 shares of common stock. Each warrant had an exercise price of $1.56 per share of Company common stock and the exercise contributed $1,638,000 in total additional cash and equity. | |||||||||||||||||
During the month of March 2014, certain holders of the warrants to purchase Company common stock issued in the October and December 2011 equity transaction exercised their right to purchase 37,574 shares of common stock. Each warrant had an original exercise price of $1.053 that was reduced in accordance with the terms of the warrant for dilution as the result of subsequent offerings to a revised exercise price of $0.944 per share of Company common stock. This created a liability of $35,470 as the stock had not been issued by the transfer agent as of the end of March, however, shares of common stock were issued during April in compliance with the contractual terms of the warrant. | |||||||||||||||||
During the month of March 2014, certain holders of the warrants to purchase Company common stock issued in the October and December 2011 equity transaction exercised their right to purchase 271,091 shares of common stock. Each warrant had an original exercise price of $1.053 that was reduced in accordance with the terms of the warrant for dilution as the result of subsequent offerings to a current exercise price of $0.944 per share of Company common stock and the exercise contributed $255,910 in total additional cash and equity. | |||||||||||||||||
During the month of March 2014, the holders of the warrants to purchase Company common stock issued in the August 2013 equity transaction exercised their right to purchase 5,648,738 shares of common stock. Each warrant had an exercise price of $0.72 per share of Company common stock and the exercise contributed $4,067,091 in total additional cash and equity. | |||||||||||||||||
The gross proceeds from the exercise of the common stock warrants exercised were $5,961,001 during the nine months ended March 31, 2014, net of the $35,470 liability for the shares of common stock which were not issued until April 2014. | |||||||||||||||||
Warrant liability and related offering cost deferral | |||||||||||||||||
Based on the guidance contained in ASC 815 "Derivatives and Hedging", management has concluded that the warrants issued in the October and December 2011 underwritten registered offering of 2,500,000 shares of common stock should be classified as a derivative liability and has recorded a liability at fair value. The Company determined the fair value of the warrants using the Black-Scholes fair value model. The Company determined the fair value of the warrants on the date of the offering to be as disclosed in the tables below. The Company has recognized a change in fair value as described in the tables below: | |||||||||||||||||
Change in fair value of the derivative warrant liability for the three months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Three months ended | Three months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Change in fair value of the derivative warrant liability | $ | 1,095,000 | $ | (109,000 | ) | ||||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011. | |||||||||||||||||
Three months ended | Three months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 650,003 | $ | 20,000 | 650,003 | $ | 218,000 | |||||||||||
Change in fair value | 650,003 | 1,004,000 | (99,000 | ) | |||||||||||||
Warrants corrected | 10,869 | - | - | - | |||||||||||||
Warrants exercised | (258,943 | ) | (423,000 | ) | - | - | |||||||||||
Balance, end of the period | 401,929 | $ | 601,000 | 650,003 | $ | 119,000 | |||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011. | |||||||||||||||||
Three months ended | Three months ended | ||||||||||||||||
31-Mar-14 | March 31, 2013 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 63,598 | $ | 3,000 | 63,598 | $ | 22,000 | |||||||||||
Change in fair value | 63,598 | 91,000 | 63,598 | (10,000 | ) | ||||||||||||
Warrants corrected | (400 | ) | - | - | - | ||||||||||||
Warrants exercised | (12,148 | ) | (17,000 | ) | - | - | |||||||||||
Balance, end of the period | 51,050 | $ | 77,000 | 63,598 | $ | 12,000 | |||||||||||
Total fair value of warrant derivative liability at March 31, 2014 and 2013 | $ | 678,000 | $ | 131,000 | |||||||||||||
Change in fair value of the derivative warrant liability for the nine months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Nine months ended | Nine months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Change in fair value | $ | 1,014,000 | $ | (183,000 | ) | ||||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011. | |||||||||||||||||
Nine months ended | Nine months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 650,003 | $ | 94,000 | 650,003 | $ | 286,000 | |||||||||||
Change in fair value | 650,003 | 914,000 | 650,003 | (167,000 | ) | ||||||||||||
Warrants corrected | 10,869 | 16,000 | |||||||||||||||
Warrants exercised | (258,943 | ) | (423,000 | ) | - | - | |||||||||||
Balance, end of the period | 401,929 | $ | 601,000 | 650,003 | $ | 119,000 | |||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011. | |||||||||||||||||
Nine months ended | Nine months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 63,598 | $ | 10,000 | 63,598 | $ | 28,000 | |||||||||||
Change in fair value | 63,598 | 85,000 | 63,598 | (16,000 | ) | ||||||||||||
Warrants corrected | (400 | ) | (1,000 | ) | |||||||||||||
Warrants exercised | (12,148 | ) | (17,000 | ) | - | - | |||||||||||
Balance, end of the period | 51,050 | $ | 77,000 | 63,598 | $ | 12,000 | |||||||||||
Total fair value of warrant derivative liability at March 31, 2014 and 2013 | $ | 678,000 | $ | 131,000 | |||||||||||||
1 Quantity of warrants either issued or outstanding as of the date of valuation. | |||||||||||||||||
Warrants | |||||||||||||||||
The following table summarizes the warrants outstanding as of the beginning of the fiscal year, warrants exercised and warrants issued during the year and weighted average prices for each category. | |||||||||||||||||
Weighted average | |||||||||||||||||
Warrants | exercise price | ||||||||||||||||
Outstanding as of June 30, 2013 | 1,957,033 | $ | 1.38 | ||||||||||||||
Warrants issued | 5,648,738 | 0.72 | |||||||||||||||
Warrants corrected | 10,869 | 0.94 | |||||||||||||||
Warrants exercised | (6,969,829 | ) | 0.86 | ||||||||||||||
Outstanding as of March 31, 2014 | 646,811 | $ | 1.14 | ||||||||||||||
Warrants outstanding as of March 31, 2014 | |||||||||||||||||
Quantity | Expiration date | Exercise price | |||||||||||||||
6,000 | 8-Jun-15 | $ | 1.18 | ||||||||||||||
25,000 | 27-Jul-15 | 2 | |||||||||||||||
157,832 | 21-Nov-15 | 1.56 | |||||||||||||||
401,929 | 19-Oct-16 | 0.944 | |||||||||||||||
51,050 | 7-Dec-16 | 0.944 | |||||||||||||||
5,000 | 27-Jun-17 | 0.98 | |||||||||||||||
646,811 | $ | 1.14 |
Related_Party_Transaction
Related Party Transaction | 9 Months Ended | ||
Mar. 31, 2014 | |||
Related Party Transaction [Abstract] | ' | ||
Related Party Transaction | ' | ||
10 | Related Party Transaction | ||
During the nine months ended March 31, 2014 and 2013, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company's Chairman and Chief Executive Officer, to modify and maintain the Company's web interfaced data collection application to aggregate patient data in a controlled environment. The Audit Committee and Board of Directors approved the use of the ongoing services of APEX Data Systems. Mr. Babcock recused himself from the Board vote due to his conflict of interest. The cost recorded during nine months ended March 31, 2014 and 2013 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection application was $12,720 and $10,960. An additional $9,000 was spent on the implementation of Customer Relationship Management software in the nine months ended March 31, 2014. |
Loss_per_Share_Tables
Loss per Share (Tables) | 9 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Loss per Share [Abstract] | ' | ||||||||
Schedule of Antidilutive Securities Excluded from Computation of Loss per Share | ' | ||||||||
Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2014 and 2013, were as follows: | |||||||||
March 31, | |||||||||
2014 | 2013 | ||||||||
Series B preferred stock | 59,065 | 59,065 | |||||||
Common stock warrants | 646,811 | 1,957,033 | |||||||
Common stock options | 2,324,072 | 2,312,072 | |||||||
Total potential dilutive securities | 3,029,948 | 4,328,170 |
Inventory_Tables
Inventory (Tables) | 9 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory [Abstract] | ' | ||||||||
Schedule of Components of Inventory | ' | ||||||||
Inventory consisted of the following at March 31, 2014 and June 30, 2013: | |||||||||
March 31, | June 30, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 165,657 | $ | 167,671 | |||||
Work in process | 181,457 | 195,323 | |||||||
Finished goods | 39,906 | 42,577 | |||||||
$ | 387,020 | $ | 405,571 |
ShareBased_Compensation_Tables
Share-Based Compensation (Tables) | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Share-Based Compensation [Abstract] | ' | ||||||||||||||||
Schedule of Share-Based Compensation Expense | ' | ||||||||||||||||
The following table presents the share-based compensation expense recognized during the three and nine months ended March 31, 2014 and 2013: | |||||||||||||||||
Three months | Nine months | ||||||||||||||||
ended March 31, | ended March 31, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Cost of product sales | $ | 4,500 | $ | 10,164 | $ | 13,421 | $ | 30,492 | |||||||||
Research and development expenses | 3,482 | 7,607 | 10,447 | 25,042 | |||||||||||||
Sales and marketing expenses | 879 | 1,386 | 2,636 | 4,568 | |||||||||||||
General and administrative expenses | 4,572 | 8,423 | 38,713 | 25,267 | |||||||||||||
Total share-based compensation | $ | 13,433 | $ | 27,580 | $ | 65,217 | $ | 85,369 | |||||||||
Schedule of Stock Option within Share-based Compensation Plans | ' | ||||||||||||||||
A summary of stock options within the Company's share-based compensation plans as of March 31, 2014 was as follows: | |||||||||||||||||
Weighted | |||||||||||||||||
Weighted | Average | ||||||||||||||||
Average | Remaining | Aggregate | |||||||||||||||
Number of | Exercise | Contractual | Intrinsic | ||||||||||||||
Options | Price | Term | Value | ||||||||||||||
Outstanding at March 31, 2014 | 2,324,072 | $ | 1.82 | 4.3 | $ | 2,050,334 | |||||||||||
Vested and expected to vest at March 31, 2014 | 2,238,840 | $ | 1.86 | 4.23 | $ | 1,923,611 | |||||||||||
Vested and exercisable at March 31, 2014 | 2,040,732 | $ | 1.93 | 3.85 | $ | 1,714,527 |
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 9 Months Ended | ||||||||||
Mar. 31, 2014 | |||||||||||
Fair Value Measurements [Abstract] | ' | ||||||||||
Schedule of Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis and Fair Value Calculation Input Hierarchy Level | ' | ||||||||||
The table below sets forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and June 30, 2013, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category. | |||||||||||
Description | Balance at | Balance at | Input | ||||||||
31-Mar-14 | 30-Jun-13 | Hierarchy Level | |||||||||
Assets: | |||||||||||
Cash and cash equivalents | $ | 23,702,901 | $ | 2,899,927 | Level 1 | ||||||
Restricted cash | 181,194 | 181,149 | Level 1 | ||||||||
Liabilities: | |||||||||||
Warrant liability | $ | 678,000 | $ | 104,000 | Level 2 |
Shareholders_Equity_Tables
Shareholders' Equity (Tables) | 9 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Shareholders' Equity [Abstract] | ' | ||||||||||||||||
Schedule of Proceeds from Common Stock Offering | ' | ||||||||||||||||
This public offering resulted in gross proceeds of $3.7 million. The offering yielded approximately $3,279,292 in cash after expenses. | |||||||||||||||||
Gross proceeds from public offering | $ | 3,703,527 | |||||||||||||||
Underwriting discount | (185,176 | ) | |||||||||||||||
Legal and accounting expense | (184,514 | ) | |||||||||||||||
Listing expense | (48,500 | ) | |||||||||||||||
Other expense | (6,045 | ) | |||||||||||||||
Net proceeds | 3,279,292 | ||||||||||||||||
On March 21, 2014, the Company entered into a Securities Purchase Agreement with certain investors providing for the sale of a total of 5,644,300 shares of common stock for an aggregate purchase price of $14,675,180 at a price per share of $2.60 (the "Registered Direct Offering"). The Company received net proceeds from the offering of approximately $13,818,927 from the Registered Direct Offering which will be used to meet the Company's working capital needs and general corporate purposes. | |||||||||||||||||
Gross proceeds from registered direct offering | $ | 14,675,180 | |||||||||||||||
Placement agent fees | (733,759 | ) | |||||||||||||||
Legal and accounting expense | (72,494 | ) | |||||||||||||||
Listing expense | (45,000 | ) | |||||||||||||||
Other expense | (5,000 | ) | |||||||||||||||
Net proceeds | 13,818,927 | ||||||||||||||||
Schedule of Fair Value of Warrants | ' | ||||||||||||||||
Change in fair value of the derivative warrant liability for the three months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Three months ended | Three months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Change in fair value of the derivative warrant liability | $ | 1,095,000 | $ | (109,000 | ) | ||||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011. | |||||||||||||||||
Three months ended | Three months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 650,003 | $ | 20,000 | 650,003 | $ | 218,000 | |||||||||||
Change in fair value | 650,003 | 1,004,000 | (99,000 | ) | |||||||||||||
Warrants corrected | 10,869 | - | - | - | |||||||||||||
Warrants exercised | (258,943 | ) | (423,000 | ) | - | - | |||||||||||
Balance, end of the period | 401,929 | $ | 601,000 | 650,003 | $ | 119,000 | |||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011. | |||||||||||||||||
Three months ended | Three months ended | ||||||||||||||||
31-Mar-14 | March 31, 2013 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 63,598 | $ | 3,000 | 63,598 | $ | 22,000 | |||||||||||
Change in fair value | 63,598 | 91,000 | 63,598 | (10,000 | ) | ||||||||||||
Warrants corrected | (400 | ) | - | - | - | ||||||||||||
Warrants exercised | (12,148 | ) | (17,000 | ) | - | - | |||||||||||
Balance, end of the period | 51,050 | $ | 77,000 | 63,598 | $ | 12,000 | |||||||||||
Total fair value of warrant derivative liability at March 31, 2014 and 2013 | $ | 678,000 | $ | 131,000 | |||||||||||||
Change in fair value of the derivative warrant liability for the nine months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Nine months ended | Nine months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Change in fair value | $ | 1,014,000 | $ | (183,000 | ) | ||||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on October 19, 2011. | |||||||||||||||||
Nine months ended | Nine months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 650,003 | $ | 94,000 | 650,003 | $ | 286,000 | |||||||||||
Change in fair value | 650,003 | 914,000 | 650,003 | (167,000 | ) | ||||||||||||
Warrants corrected | 10,869 | 16,000 | |||||||||||||||
Warrants exercised | (258,943 | ) | (423,000 | ) | - | - | |||||||||||
Balance, end of the period | 401,929 | $ | 601,000 | 650,003 | $ | 119,000 | |||||||||||
Change in fair value of the derivative warrant liability for purchaser warrants and underwriter warrants contained in an equity transaction on December 7, 2011. | |||||||||||||||||
Nine months ended | Nine months ended | ||||||||||||||||
31-Mar-14 | 31-Mar-13 | ||||||||||||||||
Quantity1 | Amount | Quantity1 | Amount | ||||||||||||||
Balance, beginning of the period | 63,598 | $ | 10,000 | 63,598 | $ | 28,000 | |||||||||||
Change in fair value | 63,598 | 85,000 | 63,598 | (16,000 | ) | ||||||||||||
Warrants corrected | (400 | ) | (1,000 | ) | |||||||||||||
Warrants exercised | (12,148 | ) | (17,000 | ) | - | - | |||||||||||
Balance, end of the period | 51,050 | $ | 77,000 | 63,598 | $ | 12,000 | |||||||||||
Total fair value of warrant derivative liability at March 31, 2014 and 2013 | $ | 678,000 | $ | 131,000 | |||||||||||||
1 Quantity of warrants either issued or outstanding as of the date of valuation. | |||||||||||||||||
Schedule of Warrants Activity | ' | ||||||||||||||||
The following table summarizes the warrants outstanding as of the beginning of the fiscal year, warrants exercised and warrants issued during the year and weighted average prices for each category. | |||||||||||||||||
Weighted average | |||||||||||||||||
Warrants | exercise price | ||||||||||||||||
Outstanding as of June 30, 2013 | 1,957,033 | $ | 1.38 | ||||||||||||||
Warrants issued | 5,648,738 | 0.72 | |||||||||||||||
Warrants corrected | 10,869 | 0.94 | |||||||||||||||
Warrants exercised | (6,969,829 | ) | 0.86 | ||||||||||||||
Outstanding as of March 31, 2014 | 646,811 | $ | 1.14 | ||||||||||||||
Warrants outstanding as of March 31, 2014 | |||||||||||||||||
Quantity | Expiration date | Exercise price | |||||||||||||||
6,000 | 8-Jun-15 | $ | 1.18 | ||||||||||||||
25,000 | 27-Jul-15 | 2 | |||||||||||||||
157,832 | 21-Nov-15 | 1.56 | |||||||||||||||
401,929 | 19-Oct-16 | 0.944 | |||||||||||||||
51,050 | 7-Dec-16 | 0.944 | |||||||||||||||
5,000 | 27-Jun-17 | 0.98 | |||||||||||||||
646,811 | $ | 1.14 |
Loss_per_Share_Details
Loss per Share (Details) | 9 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Antidilutive securities excluded from computation of earnings per share, amount | 3,029,948 | 4,328,170 |
Series B Preferred Stock [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Antidilutive securities excluded from computation of earnings per share, amount | 59,065 | 59,065 |
Warrant [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Antidilutive securities excluded from computation of earnings per share, amount | 646,811 | 1,957,033 |
Employee Stock Option [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Antidilutive securities excluded from computation of earnings per share, amount | 2,324,072 | 2,312,072 |
Inventory_Details
Inventory (Details) (USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
Inventory [Abstract] | ' | ' |
Raw materials | $165,657 | $167,671 |
Work in process | 181,457 | 195,323 |
Finished goods | 39,906 | 42,577 |
Total inventory | $387,020 | $405,571 |
ShareBased_Compensation_Schedu
Share-Based Compensation (Schedule of Share-Based Compensation Expense) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | $13,433 | $27,580 | $65,217 | $85,369 |
Unrecognized compensation expense related to stock-based options and awards | 29,192 | ' | 29,192 | ' |
Unrecognized compensation expense related to stock-based options and awards, weighted-average recognition period | ' | ' | '10 months 13 days | ' |
Stock options, maximum term | ' | ' | '10 years | ' |
Cost of Product Sales [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 4,500 | 10,164 | 13,421 | 30,492 |
Research and Development Expenses [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 3,482 | 7,607 | 10,447 | 25,042 |
Sales and Marketing Expenses [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 879 | 1,386 | 2,636 | 4,568 |
General and Administration Expenses [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | $4,572 | $8,423 | $38,713 | $25,267 |
ShareBased_Compensation_Schedu1
Share-Based Compensation (Schedule of Stock Option Activity) (Details) (USD $) | 0 Months Ended | 9 Months Ended | ||
Sep. 05, 2013 | Sep. 06, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Number of Options | ' | ' | ' | ' |
Outstanding at March 31, 2014 | ' | ' | 2,324,072 | ' |
Vested and expected to vest at March 31, 2014 | ' | ' | 2,238,840 | ' |
Vested and exercisable at March 31, 2014 | ' | ' | 2,040,732 | ' |
Weighted Average Exercise Price | ' | ' | ' | ' |
Outstanding at March 31, 2014 | ' | ' | $1.82 | ' |
Vested and expected to vest at March 31, 2014 | ' | ' | $1.86 | ' |
Vested and exercisable at March 31, 2014 | ' | ' | $1.93 | ' |
Weighted Average Remaining Contractual Term | ' | ' | ' | ' |
Outstanding at March 31, 2014 | ' | ' | '4 years 3 months 18 days | ' |
Vested and expected to vest at March 31, 2014 | ' | ' | '4 years 2 months 23 days | ' |
Vested and exercisable at March 31, 2014 | ' | ' | '3 years 10 months 6 days | ' |
Average Intrinsic Value | ' | ' | ' | ' |
Outstanding at March 31, 2014 | ' | ' | $2,050,334 | ' |
Vested and expected to vest at March 31, 2014 | ' | ' | 1,923,611 | ' |
Vested and exercisable at March 31, 2014 | ' | ' | 1,714,527 | ' |
Options exercised | ' | ' | 26,333 | 31,700 |
Aggregate intrinsic value of option exercised | ' | ' | 15,130 | 13,866 |
Stock options granted | 50,000 | 15,000 | 65,000 | ' |
Stock options issued, exercise price | $0.58 | $0.59 | ' | ' |
Fair value of stock options granted | $25,150 | $6,906 | ' | ' |
Exercise price | $0.58 | $0.59 | ' | ' |
Expected term | '5 years | '5 years | ' | ' |
Volatility | 132.31% | 132.31% | ' | ' |
Discount rate | 1.85% | 1.77% | ' | ' |
Commitments_and_Contingencies_
Commitments and Contingencies (Details) (Patent Rights Know-how and License Agreements [Member]) | Mar. 31, 2014 |
Patent Rights Know-how and License Agreements [Member] | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Percentage of royalty payment on net sales | 1.00% |
Fair_Value_Measurements_Detail
Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $) | Mar. 31, 2014 | Jun. 30, 2013 |
Level 1 [Member] | ' | ' |
Assets: | ' | ' |
Cash and cash equivalents | $23,702,901 | $2,899,927 |
Restricted cash | 181,194 | 181,149 |
Level 2 [Member] | ' | ' |
Liabilities: | ' | ' |
Warrant liability | $678,000 | $104,000 |
Preferred_Dividends_Details
Preferred Dividends (Details) (USD $) | 9 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Dividends Payable [Line Items] | ' | ' |
Preferred dividends paid | $10,632 | $10,632 |
Shareholders_Equity_Common_and
Shareholders' Equity (Common and Preferred Stock Transactions) (Details) (USD $) | 0 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | |||||||||
Mar. 21, 2014 | Aug. 29, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Jan. 31, 2014 | Dec. 31, 2013 | Jun. 30, 2013 | Aug. 29, 2013 | Aug. 29, 2013 | Mar. 21, 2014 | Aug. 29, 2013 | Jan. 31, 2014 | Dec. 31, 2011 | Aug. 29, 2013 | Jan. 31, 2014 | |
Common Unit Warrants [Member] | Preferred Unit Warrants [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Series D Preferred Stock [Member] | Series D Preferred Stock [Member] | ||||||||||
Class of Stock [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,644,300 | 3,800,985 | ' | 2,500,000 | 1,670 | ' |
Number of shares covered by each warrant | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.816 | ' | ' | ' | ' | ' | ' | ' |
Number of shares number of shares covered by warrant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,525.23 | ' | ' | ' | ' | ' | ' |
Stock issued, price per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.60 | $0.54 | ' | ' | $1,000 | ' |
Exercise price | ' | ' | 1.14 | ' | 1.14 | ' | ' | ' | 1.38 | 0.72 | 0.72 | ' | ' | ' | ' | ' | ' |
Warrant term | ' | ' | ' | ' | ' | ' | ' | ' | ' | '24 months | '24 months | ' | ' | ' | ' | ' | ' |
Number of common shares issuable upon conversion | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,869.15 | ' |
Beneficial conversion feature | ' | ' | ' | ' | $726,378 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gross proceeds from public offering | 14,675,180 | 3,703,527 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Underwriting discount | ' | -185,176 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Placement agent fees | -733,759 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Legal and accounting expense | -72,494 | -184,514 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Listing expense | -45,000 | -48,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other expense | -5,000 | -6,045 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net proceeds | $13,818,927 | $3,279,292 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares converted | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,670 |
Number of common shares issued upon conversion | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,121,480 | ' | ' | ' |
Common stock, shares outstanding | ' | ' | 54,181,444 | ' | 54,181,444 | ' | 41,540,982 | 38,419,502 | 34,618,517 | ' | ' | ' | ' | ' | ' | ' | ' |
Shareholders_Equity_Warrant_Ex
Shareholders' Equity (Warrant Exercises) (Details) (USD $) | 9 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | |||||
Mar. 31, 2014 | Mar. 31, 2013 | Jun. 30, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2011 | Mar. 31, 2014 | Dec. 31, 2011 | Mar. 31, 2014 | |
Warrants Issued in November 2010 [Member] | Warrants Issued in 2011 [Member] | Warrants Issued in 2011 [Member] | Warrants Issued in 2011, Two [Member] | Warrants Issued in 2011, Two [Member] | Warrants Issued in 2013 [Member] | ||||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants exercised | 6,969,829 | ' | ' | 1,050,000 | 37,574 | ' | 271,091 | ' | 5,648,738 |
Exercise price | $0.86 | ' | ' | $1.56 | $0.94 | ' | $0.94 | ' | $0.72 |
Warrants issued, exercise price | 1.14 | ' | 1.38 | ' | ' | 1.053 | ' | 1.053 | ' |
Proceeds from exercise of warrants | $5,961,001 | $1,825 | ' | $1,638,000 | $35,470 | ' | $255,910 | ' | $4,067,091 |
Liability for shares of common stock | $35,470 | ' | ' | ' | ' | ' | ' | ' | ' |
Shareholders_Equity_Schedule_o
Shareholders' Equity (Schedule of Inputs for Fair Value Model) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |||||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ||||
Balance, beginning of period | ' | ' | 1,957,033 | ' | ||||
Warrants corrected | ' | ' | 10,869 | ' | ||||
Warrants exercised | ' | ' | -6,969,829 | ' | ||||
Balance, end of period | 646,811 | ' | 646,811 | ' | ||||
Value of warrants issued: | ' | ' | ' | ' | ||||
Change in fair value of warrant derivative liability | $1,095,000 | ($109,000) | $1,014,000 | ($183,000) | ||||
Balance, end of period | 678,000 | 131,000 | 678,000 | 131,000 | ||||
Common Stock Purchaser Warrants [Member] | ' | ' | ' | ' | ||||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ||||
Balance, beginning of period | 650,003 | [1] | 650,003 | [1] | 650,003 | [1] | 650,003 | [1] |
Warrants corrected | 10,869 | [1] | ' | [1] | 10,869 | [1] | ' | [1] |
Warrants exercised | -258,943 | [1] | ' | [1] | -258,943 | [1] | ' | [1] |
Balance, end of period | 401,929 | [1] | 650,003 | [1] | 401,929 | [1] | 650,003 | [1] |
Value of warrants issued: | ' | ' | ' | ' | ||||
Balance, beginning of period | 20,000 | 218,000 | 94,000 | 286,000 | ||||
Change in fair value of warrant derivative liability | 1,004,000 | -99,000 | 914,000 | -167,000 | ||||
Warrants corrected | ' | ' | 16,000 | ' | ||||
Warrants exercised | -423,000 | ' | -423,000 | ' | ||||
Balance, end of period | 601,000 | 119,000 | 601,000 | 119,000 | ||||
Over Allotment Warrants [Member] | ' | ' | ' | ' | ||||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ||||
Balance, beginning of period | 63,598 | [1] | 63,598 | [1] | 63,598 | [1] | 63,598 | [1] |
Warrants corrected | -400 | [1] | ' | [1] | -400 | [1] | ' | [1] |
Warrants exercised | -12,148 | [1] | ' | [1] | -12,148 | [1] | ' | [1] |
Balance, end of period | 51,050 | [1] | 63,598 | [1] | 51,050 | [1] | 63,598 | [1] |
Value of warrants issued: | ' | ' | ' | ' | ||||
Balance, beginning of period | 3,000 | 22,000 | 10,000 | 28,000 | ||||
Change in fair value of warrant derivative liability | 91,000 | -10,000 | 85,000 | -16,000 | ||||
Warrants corrected | ' | ' | -1,000 | ' | ||||
Warrants exercised | -17,000 | ' | -17,000 | ' | ||||
Balance, end of period | $77,000 | $12,000 | $77,000 | $12,000 | ||||
[1] | Quantity of warrants either issued or outstanding as of the date of valuation. |
Shareholders_Equity_Warrants_D
Shareholders' Equity (Warrants) (Details) (USD $) | 9 Months Ended |
Mar. 31, 2014 | |
Warrants | ' |
Balance, beginning of period | 1,957,033 |
Warrants issued | 5,648,738 |
Warrants corrected | 10,869 |
Warrants exercised | -6,969,829 |
Balance, end of period | 646,811 |
Weighted average exercise price | ' |
Beginning balance outstanding | 1.38 |
Warrants issued | 0.72 |
Warrants corrected | $0.94 |
Warrants exercised | $0.86 |
Ending balance outstanding | 1.14 |
Shareholders_Equity_Additional
Shareholders' Equity (Additional Information about Warrants) (Details) | Mar. 31, 2014 | Jun. 30, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 |
Range of Exercise Price One [Member] | Range of Exercise Price Two [Member] | Range of Exercise Price Four [Member] | Range of Exercise Price Five [Member] | Range of Exercise Price Six [Member] | Range of Exercise Price Seven [Member] | |||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Quantity | 646,811 | 1,957,033 | 6,000 | 25,000 | 157,832 | 401,929 | 51,050 | 5,000 |
Expiration date | ' | ' | 8-Jun-15 | 27-Jul-15 | 21-Nov-15 | 19-Oct-16 | 7-Dec-16 | 27-Jun-17 |
Exercise price | 1.14 | 1.38 | 1.18 | 2 | 1.56 | 0.944 | 0.944 | 0.98 |
Related_Party_Transaction_Deta
Related Party Transaction (Details) (Affiliated Entity [Member], USD $) | 9 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Affiliated Entity [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Maintenance costs | $12,720 | $10,960 |
Software implementation costs | $9,000 | ' |